| Patient | Emily Dickinson |
|---|---|
| Date of birth | 1971-12-10 |
| Identifiers | MRN HR-NI023-SYN; SSN (made up) 000-23-6081 |
| Document date | 2026-03-02 |
| Author | Lucinda Hartwell, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Video visit four weeks after the losartan increase and dapagliflozin start. [S]
Ms. Dickinson is seen by video from her home. The mobile phlebotomy service drew her blood this morning. Before the call she measured her blood pressure twice with her validated upper-arm cuff after five minutes' rest, and her weight, temperature, and oxygen saturation with her own devices; Dr. Hartwell counted her breathing on video. She has taken losartan 100 mg and dapagliflozin 10 mg daily for four weeks. She has had a headache only once in the past two weeks. She passes a little more urine and has had no lightheadedness, genital itching, or urinary symptoms. Her home blood pressure averages 138/84 over the past two weeks. She drinks to thirst, about 1.5 L a day. [S]
| Element | Detail |
|---|---|
| Visit format | Video visit from home, with home-measured vital signs and a home blood draw this morning |
| Headaches | Once in two weeks |
| Medication tolerance | No lightheadedness, genital itching, or urinary symptoms on dapagliflozin |
| Home blood pressure | Average 138/84 mmHg over two weeks |
| Fluids | About 1.5 L a day, to thirst |
| System | Result | Finding |
|---|---|---|
| Neurological | Negative | One mild headache in two weeks; no lightheadedness |
| Genitourinary | Negative | Slightly more urine; no dysuria, itching, or discharge |
| Cardiovascular | Negative | No palpitations or ankle swelling |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naproxen sodium 220 mg oral tablet, two tablets by mouth as needed for headache (over the counter) | Two tablets as needed, up to twice a day | Oral route | 2025-10-01 to 2026-01-12 | stopped | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 to 2026-02-02 | completed | S |
| Losartan 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-02-02 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day | Two tablets every 6 hours as needed; maximum 6 tablets a day | Oral route | 2026-01-12 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-02-02 | active | S |
| Amlodipine 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-02 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-02 | Body height | 163 | cm | S |
| 2026-03-02 | Body weight | 53.6 | kg | S |
| 2026-03-02 | Body mass index (BMI) [Ratio] | 20.2 | kg/m2 | S |
| 2026-03-02 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-03-02 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-03-02 | Heart rate | 72 | /min | S |
| 2026-03-02 | Respiratory rate | 14 | /min | S |
| 2026-03-02 | Body temperature | 36.6 | Cel | S |
| 2026-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-02 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-02 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-02 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-03-02 | Urea nitrogen [Mass/volume] in Serum or Plasma | 23 | mg/dL | 6-21 mg/dL | High | S |
| 2026-03-02 | Creatinine [Mass/volume] in Serum or Plasma | 1.32 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-03-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 48 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-03-02 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-99 mg/dL | Normal | S |
Vital signs recorded on 2026-03-02; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General (video) | Comfortable and well groomed; speaking in full sentences; respiratory rate 14 counted on video |
| Extremities (video) | She pressed on both shins for five seconds: no pitting seen |
| Mental status (video) | Alert, engaged, and dryly humorous; mood "steadier" |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificate | active | confirmed | N18.31 | S — Synthetic modern diagnosis. Bright's disease as her recorded cause of death is documented (D); what it meant in her case is a retrospective question (R), and no kidney test from her lifetime exists. |
| Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertension | active | confirmed | I12.9 | S — Synthetic modern diagnosis; severe hypertension is a retrospective interpretation (R, possible), and no blood pressure from her lifetime exists. |
| Vitamin D deficiency with a mildly raised PTH in chronic kidney disease | active | confirmed | E55.9 | S — Synthetic laboratory finding at the intake visit. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Potassium and creatinine after increasing the ARB and starting the SGLT2 inhibitor | 2 to 4 weeks after starting or increasing an ACE inhibitor, ARB, SGLT2 inhibitor, or MRA | Completed today | Potassium 4.8 mmol/L, creatinine 1.32 mg/dL, eGFR 48, four weeks after both changes |
| Examination | Standardized home blood pressure on a validated cuff | Every visit | Completed today | 136/84 mmHg today; two-week home average 138/84 |
| Examination | Weight | Every visit | Completed today | 53.6 kg on her home scale |
| Examination | Cardiac auscultation | Every visit | Deferred | Not possible at a video visit; no new cardiac symptoms. It was done three weeks after intake at the clinic visit and will be done at the home visit in June |
| Medication safety | SGLT2 inhibitor safety: volume status and genital infection | At each review after starting | Completed today | No lightheadedness or genital symptoms; fluids to thirst |
| Medication safety | Medication review: NSAID avoidance and dose adjustment | Every visit | Completed today | No NSAIDs; acetaminophen once in two weeks |
| Laboratory | Potassium and creatinine after starting amlodipine | Not required for a calcium-channel blocker | Not indicated | Amlodipine does not affect potassium or creatinine; the next panel is at the three-month review |
| Laboratory | eGFR and urine albumin-creatinine ratio | Twice a year at G3a A2 (KDIGO heat map) | Due | Next at the three-month review to judge the albuminuria response |
| Self-management | Sick-day rules | At each start of a RAAS blocker or SGLT2 inhibitor, and yearly | Completed today | Reviewed again by video |
Goal progress:
Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026)
Follow-up: Home visit in three months with blood and urine tests; weekly home blood pressure readings by message. Next scheduled visit 2026-06-01: home visit for the three-month kidney and blood pressure review. [S]